ClinicalTrials.gg
RecruitingNCT06084169Updated Sep 27, 2024

Investigation for Assessing the Visual Performance of Hanita Lenses Intensity SL IOL in Comparison to Alcon Panoptix IOL

An interventional study of Intra Ocular Lens (IOL) Implant in Cataract, sponsored by Hanita Lenses. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by Hanita Lenses · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cataract by Hanita Lenses — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Hanita Lenses.

Started
2023
with 3 others
No phase
8 of 10
2 open now
Registered
7th of 10
by date

Among the 10 studies in Cataract by Hanita Lenses, this one is one of 4 that started in 2023, is one of 8 with no phase, and was the 7th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 10 studies in Cataract by Hanita Lenses are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cataract by Hanita Lenses, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the visual performance between Intensity SL IOL and Panoptix IOL in men and women diagnosed with cataract who require cataract surgery procedure that meet the inclusion criteria and provide written informed consent will be enrolled in the study.

The main questions it aims to answer are:

  1. To show non-inferiority in binocular distance corrected visual acuity for far, intermediate and near distances after Trifocal IOL implantation.
  2. To show non-inferiority in the Defocus Curve measurement
  3. To show non-inferiority in Contrast Sensitivity measurement
  4. To show non-inferiority in patient satisfaction

Participants will attend a total of 10 study visits: 1 preoperative visit, 2 operations and 7 postoperative visits.

Read the detailed description

This study is a single center, prospective, (1:1) randomized, unblinded, controlled study carried out in Germany according to Art. 74 MDR (PMCF study) or according to Art. 82 MDR / § 47 Para. 3 MPDG is carried out.

The lead investigator at the Heidelberg University Eye Clinic is Prof. Dr. Gerd U. Auffarth.

This study examines the visual performance of the trifocal Hanita Lenses Intensity SL IOL (study lens) compared to the trifocal Alcon PanOptix IOL (comparison lens) in bilaterally implanted patients. Clinical investigations including patient-reported results from the test group will be compared with those from the control group.

A total of approximately 58 patients will be included at 1 clinical center. Subjects participating in the study will attend a maximum of 10 study visits (1 preoperative, 2 operative and up to 7 postoperative) over a period of 3-7 months.

Only patients who have age-related cataracts will be included in the study. To participate in this study, patients must be at least 18 years old at the time of screening and a maximum preoperative corneal astigmatism of 1.0 D is permitted. All patients who would like to take part in this study will receive an information interview and further detailed study information in written form. Before a patient is admitted, he or she must sign a consent form.

The primary study endpoint is to investigate whether the binocular distance-corrected visual acuity achieved with the study lens for the distance, intermediate and near ranges is not statistically significantly inferior to the parameters achieved with the control lens.

The entire study including data processing will be carried out in accordance with EN ISO 14155:2020 Clinical Investigation of Medical Devices for Human Subjects, EN ISO 11979-7:2018: Clinical investigations of intraocular lenses for the correction of aphakia, EU MDR 2017/745, MEDDEV 2.7.1 rev. 4 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies, MPDG:2020: Medical Device Law Implementation Act, as well as applicable local regulations and the Declaration of Helsinki.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • IOL
  • Cataract
  • Hanita Lenses
  • Alcon
  • Intensity SL
  • Panoptix
  • Intra Ocular Lens
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capability to understand and sign an IRB approved form and privacy authorization
  • Age over 18 on the screening day
  • Patients with bilateral age-related cataracts and planned bilateral cataract phacoemulsification combined Intraocular Lens implantation;
  • Calculated IOL power is within range 15-30 Diopter (approximate range of axial lengths: 21-25.5mm)
  • Normal corneas with corneal astigmatism below following value, measured by Biometer

    1. 1 D if with-the-rule (steep axis is vertical, between 60-120⁰)
    2. 0.4 D if against-the-rule (steep axis is horizontal, 0-30⁰ or 150-180⁰)
    3. 0.7 D if oblique (not one of the cases above)
  • Post-operative best corrected distance visual acuity expected to be 0.3 logMAR or lower
  • Patient motivated for trifocal IOL after screening by surgeon, willing and able to conform to the study requirements
  • Fundus visualization is possible
  • Absence of retinal or optic nerve diseases
  • Clear intraocular media other than cataract
  • When scheduling the first surgery, the patient shall commit to:

    1. Availability for the follow-up visits - 1 day, 1 week and 1 month after the first surgery
    2. Availability for the second surgery - one week to two months after the first surgery
    3. Availability for the follow-up visits - 1 day, 1 week, 1 month and 3 months after the second surgery

Exclusion criteria

Exclusion Criteria:

  • Difficulty for cooperation (distance from their home, general health conditions)
  • Previous ocular/corneal surgery that may affect refraction accuracy or visual acuity.

    18 Protocol ID.: ISL-01 Version:2 Date: 20 Mar 2023

  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
  • History or evidence of any ocular disease that may affect visual acuity (i.e. uncontrolled glaucoma, ocular injury, corneal pathologies, retinal pathologies in general and macular pathologies in particular, diabetic retinopathy, uveitis, aniridia or iris atrophy, vitreous pathologies (patients with vitreous separation or floaters can be included).
  • Rubella cataract.
  • Amblyopia
  • Use of systemic or ocular medication that might affect vision
  • Patients with, strabismus, former fruste keratoconus or keratoconus
  • Usage of contact lenses during participation
  • Any other ocular condition that may predispose a subject to future complications or contraindicate implantation of the trifocal lens.
  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions)
  • Pregnant, lactating, or planning to become pregnant during the course of the trial.
  • Allergy or intolerance to required study medications (including antibiotic).
  • Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days.
  • Traumatic cataract
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Active comparator
    Intensity SL IOL

    29 patients will be implanted bilaterally with Intensity SL IOL

    Device: Intra Ocular Lens (IOL) Implant

  • Active comparator
    Panoptix IOL

    29 patients will be implanted bilaterally with PanOptix IOL

    Device: Intra Ocular Lens (IOL) Implant

Interventions

  • DeviceIntra Ocular Lens (IOL) Implant

    Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye

    Also known as: Panoptix Intra Ocular Lens (IOL) Implant

06

What researchers measure

Primary outcomes

  1. Binocular distance corrected visual acuity

    To show non-inferiority in binocular distance corrected visual acuity for far, intermediate and near distances after Trifocal IOL implantation. Visual acuity will be performed by using ETDRS charts. All results will be expressed in logMAR. Visual acuity will be measured in photopic conditions.

    Time frame: 3 months (90-120 days) post second eye operation

Secondary outcomes

  1. Defocus Curve

    To show non-inferiority in the Defocus Curve measurement by using ETDRS charts. The test will be performed using a phoropter to create defocus in 0.5D increments, starting from 1D to -4D relative to emmetropia so that the patient will be corrected for far vision.

    Time frame: 3 months (90-120 days) post second eye operation

  2. Contrast Sensitivity

    To show non-inferiority in Contrast Sensitivity measurement by using VectorVision at mesopic and photopic conditions. Luminance for photopic conditions will be 85cd/m² and 5cd/m² for mesopic conditions. Small deviations are allowed. The working interval for photopic conditions is 75-95cd/m² and for mesopic conditions is 5-15cd/m².

    Time frame: 3 months (90-120 days) post second eye operation

  3. Patient satisfaction

    To show non-inferiority in patient satisfaction by using the modified VF-14 questionnaire for quality of life, in addition to satisfaction questionnaire.

    Time frame: 3 months (90-120 days) post second eye operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 29 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2023
First posted
Oct 16, 2023
StartActual
Jul 13, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Mar 1, 2026
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084169
Lead sponsor
Hanita Lenses
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jul 13, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Sep 27, 2024

Study contacts

Raquel Willrich Amroussi, M.A
Contact
raquel.willrichamroussi@med.uni-heidelberg.de
49 6221 56-36849
Auffarth Gerd U., Prof.
principal investigator · Universitäts-Augenklinik Heidelberg International Vision Correction Research Centre (IVCRC)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion